News
Vaginal Candida (yeast) Infections - FDA Approval For Terconazole Suppositories
The Perrigo Company (Nasdaq: PRGO; TASE) announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to manufacture and market terconazole vaginal suppositories, 80 mg.
The product is the AB-rated equivalent to Ortho-McNeil Pharmaceutical's Terazol(R) 3 Vaginal Suppositories, 80 mg, an anti-fungal medication indicated for the treatment of vaginal candida (yeast) infections. Perrigo is currently the only approved generic for this product. Shipments will begin immediately. According to NDC data, annual U.S. sales are approximately $8.5 million.
The Perrigo Company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter (OTC) pharmaceutical and nutritional products for the store brand market. Store brand products are sold by food, drug, mass merchandise, dollar store and club store retailers under their own labels. The Company also develops, manufactures and markets prescription generic drugs, active pharmaceutical ingredients and consumer products, and operates manufacturing facilities in the United States, Israel, United Kingdom, Mexico and Germany.